ABSTRACT Background Hands undergo age‐related changes in volume and skin quality. This 18‐month exploratory study evaluated safety and effectiveness of VYC‐17.5 L for hand rejuvenation. Methods Participants (≥ 35 years) with moderate‐to‐extreme Allergan Hand Volume Deficit Scale (AHVDS) scores received VYC‐17.5L in both hands on day 1, with optional touch‐up on day 30. Effectiveness was assessed by AHVDS responder rate (≥ 1‐grade improvement from baseline per hand) at months 1, 3 (primary effectiveness timepoint), and at 3‐month intervals through month 18; investigator‐ and participant‐Global Aesthetic Improvement Scale (GAIS); hand Self‐Perception of Age (SPA); and skin quality measurements. Safety was evaluated throughout. Results Seventy‐five participants (94.7% female; mean age, 53.89 years) had both hands injected with VYC‐17.5L (median, 2.0 mL/hand), and 60.0% of hands received touch‐up (median, 1.0 mL/hand). The primary endpoint was met: 100.0% of hands were AHVDS responders at month 3. The 100% response rate was maintained through month 6, and the majority of participants (> 65%) were responders through month 18. Most hands (≥ 85%) improved on investigator‐ and participant‐GAIS through month 12. SPA improved by 5 to 6 years. Significant skin quality improvements persisted to 12 months. Twenty‐two (29.3%) participants experienced treatment‐related adverse events; most were mild or moderate in severity with a mean duration of 45.1 days, and none led to study discontinuation. Conclusion VYC‐17.5L is an effective treatment for improving hand volume deficit, with aesthetic benefits lasting 18 months.
Greiner‐Krüger et al. (Sun,) studied this question.